Literature DB >> 11103749

Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients.

D G Bailey1, G K Dresser, J H Kreeft, C Munoz, D J Freeman, J R Bend.   

Abstract

OBJECTIVES: To determine whether unprocessed grapefruit can cause a drug interaction, whether the active ingredients are naturally occurring, and whether specific furanocoumarins or flavonoids are involved.
METHODS: The oral pharmacokinetics of felodipine and its dehydrofelodipine metabolite were determined after administration of felodipine 10 mg extended-release tablet with 250 mL commercial grapefruit juice, homogenized grapefruit segments, or extract of segment-free parts equivalent to one unprocessed fruit or water in a randomized four-way crossover study. Inhibition of recombinant CYP3A4 by furanocoumarins (bergamottin, 6',7'-epoxybergamottin, 6',7'-dihydroxybergamottin) and flavonoids (naringenin optical isomers) was determined. Furanocoumarin and naringenin precursor (naringin) concentrations were measured in each grapefruit treatment.
RESULTS: Felodipine AUC with commercial grapefruit juice, grapefruit segments, or grapefruit extract was on average 3-fold higher than that with water. Felodipine peak concentration was higher, but the half-life was unchanged. The dehydrofelodipine/felodipine AUC ratio was reduced. The furanocoumarins produced mechanism-based and competitive inhibition of CYP3A4. Bergamottin was the most potent mechanism-based inhibitor. Naringenin isomers produced only competitive inhibition. Bergamottin, 6',7'-dihydroxybergamottin, and naringin concentrations varied among grapefruit treatments but were sufficient to inhibit markedly in vitro CYP3A4 activity.
CONCLUSIONS: Unprocessed grapefruit can cause a drug interaction with felodipine. The active ingredients are naturally occurring in the grapefruit. Bergamottin is likely important in drug interactions with commercial grapefruit juice. 6',7'-Dihydroxybergamottin and naringin may be more important in grapefruit segments because they are present in higher concentrations. Any therapeutic concern for a drug interaction with commercial grapefruit juice should now be extended to include whole fruit and possibly confectioneries made from grapefruit peel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11103749     DOI: 10.1067/mcp.2000.110774

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  33 in total

1.  Drug-phytochemical interactions.

Authors:  Costas Ioannides
Journal:  Inflammopharmacology       Date:  2003       Impact factor: 4.473

2.  Isothiocyanate-drug interactions in the human adenocarcinoma cell line Caco-2.

Authors:  Katarzyna Lubelska; Irena Misiewicz-Krzemińska; Małgorzata Milczarek; Jolanta Krzysztoń-Russjan; Elżbieta Anuszewska; Karolina Modzelewska; Katarzyna Wiktorska
Journal:  Mol Cell Biochem       Date:  2012-04-18       Impact factor: 3.396

3.  Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.

Authors:  Wenjie Jessie Lu; Valentina Ferlito; Cong Xu; David Alastair Flockhart; Salvatore Caccamese
Journal:  Chirality       Date:  2011-09-22       Impact factor: 2.437

4.  Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.

Authors:  Gareth E Lim; Timao Li; Harpal S Buttar
Journal:  Exp Clin Cardiol       Date:  2003

Review 5.  Grapefruit-medication interactions: forbidden fruit or avoidable consequences?

Authors:  David G Bailey; George Dresser; J Malcolm O Arnold
Journal:  CMAJ       Date:  2012-11-26       Impact factor: 8.262

Review 6.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

7.  Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect.

Authors:  Hsia-Lien Lin; Cesar Kenaan; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2012-02-16       Impact factor: 3.922

Review 8.  Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs.

Authors:  Bernice Wright; Jeremy P E Spencer; Julie A Lovegrove; Jonathan M Gibbins
Journal:  Cardiovasc Res       Date:  2012-09-27       Impact factor: 10.787

9.  Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport.

Authors:  Shuzhong Zhang; Xinning Yang; Marilyn E Morris
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

10.  Cytochrome P450 isoenzymes in rat and human liver microsomes associate with the metabolism of total coumarins in Fructus Cnidii.

Authors:  Xiao Hu; Wei Huang; Yuan Yang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-04       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.